Prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation

被引:0
作者
Masuda, Yasutaka [1 ]
Honda, Akira [1 ]
Oyama, Takashi [1 ]
Masamoto, Yosuke [2 ]
Kurokawa, Mineo [1 ,2 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo Hosp, Dept Cell Therapy & Transplantat Med, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan
基金
日本学术振兴会;
关键词
Fluid retention; Cavity effusion; Allogeneic hematopoietic stem cell transplant; PERICARDIAL-EFFUSION; ADULT PATIENTS; TOXICITY; CRITERIA; DISEASE; BLOOD; MICROANGIOPATHY; MORTALITY; INDEX;
D O I
10.1007/s12185-025-03949-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fluid retention presenting as effusions in body cavities is sometimes encountered following allogeneic stem cell transplantation (allo-HSCT). It is unclear whether cavity effusions at independent sites may serve as cumulative correlates of fluid overload and whether a higher number of effusion sites are associated with a worse prognosis. Here, we comprehensively reviewed pleural, peritoneal, and pericardial effusions in 178 first allo-HSCT recipients retrospectively. A total of 123 (69.1%) patients developed effusions in any cavity. New pleural, peritoneal, and pericardial effusions were found after allo-HSCT in 106, 88, and 53 patients, at a median of 38.0 (range, 2-2950), 22.5 (range, 2-1324), and 40 (range, 2-945) days, respectively. The cumulative incidence at day 100 was 41.0%, 40.4%, and 20.8%, respectively. Of the 92 patients who presented with effusions by day 100, 28 patients presented with effusion in a single cavity, 39 in two cavities, and 25 in all three cavities. The 2-year overall survival rates of patients with effusions in zero, one, two, and three cavities by day 100 were 86.1%, 60.0%, 59.6%, and 18.8%, respectively, showing an additive adverse association with outcome. Prospective studies to further characterize fluid dynamics following allo-HSCT are warranted.
引用
收藏
页码:833 / 847
页数:15
相关论文
共 29 条
  • [1] Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
    Armand, Philippe
    Kim, Haesook T.
    Logan, Brent R.
    Wang, Zhiwei
    Alyea, Edwin P.
    Kalaycio, Matt E.
    Maziarz, Richard T.
    Antin, Joseph H.
    Soiffer, Robert J.
    Weisdorf, Daniel J.
    Rizzo, J. Douglas
    Horowitz, Mary M.
    Saber, Wael
    [J]. BLOOD, 2014, 123 (23) : 3664 - 3671
  • [2] Defining the Intensity of Conditioning Regimens: Working Definitions
    Bacigalupo, Andrea
    Ballen, Karen
    Rizzo, Doug
    Giralt, Sergio
    Lazarus, Hillard
    Ho, Vincent
    Apperley, Jane
    Slavin, Shimon
    Pasquini, Marcelo
    Sandmaier, Brenda M.
    Barrett, John
    Blaise, Didier
    Lowski, Robert
    Horowitz, Mary
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) : 1628 - 1633
  • [3] Malignant ascites: Current therapy options and treatment prospects
    Berger, Julia M.
    Preusser, Matthias
    Berghoff, Anna S.
    Bergen, Elisabeth S.
    [J]. CANCER TREATMENT REVIEWS, 2023, 121
  • [4] Pericardial effusion post transplantation predicts inferior overall survival following allo-hematopoietic stem cell transplant
    Chen, X.
    Zou, Q.
    Yin, J.
    Wang, C.
    Xu, J.
    Wei, J.
    Zhang, Y.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 (02) : 303 - 306
  • [5] Fluid overload in the ICU: evaluation and management
    Claure-Del Granado, Rolando
    Mehta, Ravindra L.
    [J]. BMC Nephrology, 2016, 17
  • [6] Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research
    Giralt, Sergio
    Ballen, Karen
    Rizzo, Douglas
    Bacigalupo, Andreas
    Horowitz, Mary
    Pasquini, Marcelo
    Sandmaier, Brenda
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (03) : 367 - 369
  • [7] Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
  • [8] 2-F
  • [9] Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
    Gooley, Ted A.
    Chien, Jason W.
    Pergam, Steven A.
    Hingorani, Sangeeta
    Sorror, Mohamed L.
    Boeckh, Michael
    Martin, Paul J.
    Sandmaier, Brenda M.
    Marr, Kieren A.
    Appelbaum, Frederick R.
    Storb, Rainer
    McDonald, George B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (22) : 2091 - 2101
  • [10] Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation
    Ho, VT
    Cutler, C
    Carter, S
    Martin, P
    Adams, R
    Horowitz, M
    Ferrara, J
    Soiffer, R
    Giralt, S
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (08) : 571 - 575